Current COVID-19 booster shots have a problem: they last only about four months and appear to have limited efficacy in a vaccinated population. Clearly, a more durable, more efficacious vaccine is needed, but what should it be? The scientific community has not reached a consensus, according to BioSpace.
Seattle-based Icosavax’s stock plunged more than 60 percent on March 25 after the company reported topline interim data from its ongoing Phase I/II COVID-19 vaccine trial.
After producing vaccines and treatments for acute COVID-19 in record time, researchers and drugmakers are turning to finding a cure for long COVID, a more elusive target marked by hundreds of different symptoms afflicting millions of people.
Seattle-based AltPep Corporation raised $23.15 million in a Series A financing round to take the company’s breakthrough amyloid targeting platform to development.
Part of the blame for limited testing availability for the coronavirus pandemic could fall squarely on the Centers for Disease Control (CDC), which used highly restrictive language in the health protection agency’s emergency use authorization for COVID-19 testing.